Gouw SC - Search Results

1

Factor VIII products and inhibitor development in severe hemophilia A.

Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Gouw SC, et al. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024. N Engl J Med. 2013. PMID: 23323899 Free article.

2

Cardiovascular Risk Scores among Asymptomatic Adults with Haemophilia.

Camelo RM, Caram-Deelder C, Duarte BP, Moura MCB, Costa NCM, Costa IM, Vanderlei AM, Guimarães TMR, Gouw S, Rezende SM, Bom JV. Camelo RM, et al. Arq Bras Cardiol. 2023 Sep 18;120(9):e20230004. doi: 10.36660/abc.20230004. eCollection 2023. Arq Bras Cardiol. 2023. PMID: 37729292 Free PMC article. English, Portuguese.

3

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Gouw SC, et al. Blood. 2007 Jun 1;109(11):4693-7. doi: 10.1182/blood-2006-11-056317. Epub 2007 Jan 11. Blood. 2007. PMID: 17218379 Free article.

4

Gouw SC, van der Bom JG, Marijke van den Berg H. Gouw SC, et al. Blood. 2007 Jun 1;109(11):4648-54. doi: 10.1182/blood-2006-11-056291. Epub 2007 Feb 8. Blood. 2007. PMID: 17289808 Free article.

5

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Gouw SC, et al. J Thromb Haemost. 2007 Jul;5(7):1383-90. doi: 10.1111/j.1538-7836.2007.02595.x. Epub 2007 Apr 20. J Thromb Haemost. 2007. PMID: 17456190 Free article.

6

IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.

van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J. van Helden PM, et al. Among authors: gouw sc. Br J Haematol. 2008 Aug;142(4):644-52. doi: 10.1111/j.1365-2141.2008.07232.x. Epub 2008 May 28. Br J Haematol. 2008. PMID: 18510679 Free article.

7

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice.

ter Avest PC, Fischer K, Mancuso ME, Santagostino E, Yuste VJ, van den Berg HM, van der Bom JG; CANAL Study Group. ter Avest PC, et al. J Thromb Haemost. 2008 Dec;6(12):2048-54. doi: 10.1111/j.1538-7836.2008.03187.x. Epub 2008 Oct 7. J Thromb Haemost. 2008. PMID: 18983511 Free article.

8

Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment.

Gouw SC, ter Avest PC, van Helden PM, Voorberg J, van den Berg HM. Gouw SC, et al. Haemophilia. 2009 May;15(3):712-7. doi: 10.1111/j.1365-2516.2009.01998.x. Haemophilia. 2009. PMID: 19432924

9

The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.

Gouw SC, van den Berg HM. Gouw SC, et al. Semin Thromb Hemost. 2009 Nov;35(8):723-34. doi: 10.1055/s-0029-1245105. Epub 2010 Feb 18. Semin Thromb Hemost. 2009. PMID: 20169509 Review.

10

Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.

Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP. Ter Avest PC, et al. Among authors: gouw sc. Haemophilia. 2010 May;16(102):71-9. doi: 10.1111/j.1365-2516.2010.02225.x. Haemophilia. 2010. PMID: 20536988

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82 results

Search Page